Quanterix Corp (QTRX) Stock Price, Quote & News

Company Profile

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all comp...

Industry: Medical Devices

Sector: Healthcare

Phone: 617 301 9400

Website: www.quanterix.com

Address:

Building 1, 900 Middlesex Turnpike, Billerica, United States

FinanceLegacy May. 29 at 2:41 PM

$PRZO this one should be next Israel plays are popping one at a time this one has newsss sympathy off $NEXR $PRFX $HUBC $QTRX 🤩🤩

0 · Reply

PLATINUM_TRADES May. 29 at 3:15 AM

$QTRX We in and up nicely with the 50 at $3.29 needs to break for more🩸🩸

0 · Reply

Watchingnow May. 29 at 1:15 AM

$QTRX anyone know the strike on the warrants?

0 · Reply

MBUSA May. 28 at 3:29 PM

$QTRX working

0 · Reply

SuperGreenToday May. 27 at 3:00 AM

$QTRX Share Price: $2.67 Contract Selected: Nov 20, 2026 $2.5 Calls Buy Zone: $0.55 – $0.68 Target Zone: $0.94 – $1.15 Potential Upside: 61% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

focafoca99 May. 26 at 9:38 PM

$QTRX moves Anthony Catalano into the COO role and gives him a salary, sign-on bonus, and equity package.

0 · Reply

Rufusbird May. 26 at 9:03 PM

$QTRX New CFO: Anthony Catalano Re: Linkedin: About..."includes: Operations, Supply Chain, R&D and Facilities expertise directed toward supporting life science, diagnostic, and biotechnology companies grow their platforms. Business and management proficiency: • Management expertise ranging from large public company to small biotechnology startups. • Experience with M&A, due diligence and business integrations.

3 · Reply

Grateful_84 May. 22 at 3:11 PM

$MRNO $QTRX $MEHX $PCLA High Insider hold with very low float. Help teach shorts a lesson over at $MRNO. They are on the hook for 2 Ssr violations today. Lets cross .38 to .46 and they will have to deal with a squeeze.

0 · Reply

a2zmicrocap May. 18 at 9:34 PM

$QTRX

1 · Reply

a2zmicrocap May. 18 at 9:33 PM

$QTRX

0 · Reply

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-12T22:15:56.000Z - 16 days ago

Quanterix announces CFO transition

May 12, 2026, 4:01 PM EDT - 16 days ago

Quanterix Announces Planned Transition of Chief Financial Officer

May 8, 2026, 8:00 AM EDT - 21 days ago

Quanterix Proxy statement: Proxy filing

2026-05-07T20:14:51.000Z - 21 days ago

Quanterix price target lowered to $4 from $7 at TD Cowen

2026-05-07T06:21:33.000Z - 22 days ago

Lucent Diagnostics announces collaboration with Tempus AI

TEM

2026-05-07T01:49:19.000Z - 22 days ago

Quanterix reports Q1 EPS (37c), consensus (62c)

2026-05-07T01:48:11.000Z - 22 days ago

Quanterix affirms 2026 revenue outlook $169M-$174M

May 6, 2026, 4:30 PM EDT - 22 days ago

Quanterix Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 22 days ago

Quanterix Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 22 days ago

Quanterix Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 22 days ago

Quanterix Quarterly report: Q1 2026

May 6, 2026, 4:01 PM EDT - 22 days ago

Quanterix Releases Financial Results for the First Quarter of 2026

May 6, 2026, 8:00 AM EDT - 23 days ago

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows

TEM

Apr 24, 2026, 8:33 AM EDT - 5 weeks ago

Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Quanterix Proxy statement: Proxy filing

2026-04-20T14:08:55.000Z - 5 weeks ago

Quanterix price target lowered to $4 from $8 at Canaccord

2026-04-17T12:56:49.000Z - 6 weeks ago

Quanterix, PreludeDX highlights AidaBREAST multi-omic assay

Apr 17, 2026, 8:33 AM EDT - 6 weeks ago

AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology

2026-04-15T12:40:49.000Z - 6 weeks ago

Quanterix debuts Content Innovation Engine at AACR 2026

Apr 15, 2026, 8:33 AM EDT - 6 weeks ago

Quanterix Debuts Content Innovation Engine at AACR 2026

Mar 27, 2026, 4:00 PM EDT - 2 months ago

Quanterix Corporation Announces Date of 2026 Annual Meeting

Mar 9, 2026, 1:00 PM EDT - 2 months ago

Quanterix Transcript: Leerink Global Healthcare Conference 2026

Mar 4, 2026, 11:50 AM EST - 3 months ago

Quanterix Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 4:30 PM EST - 3 months ago

Quanterix Earnings Call Transcript: Q4 2025

Mar 2, 2026, 4:30 PM EST - 3 months ago

Quanterix Annual report: Q4 2025

Mar 2, 2026, 4:30 PM EST - 3 months ago

Quanterix Earnings release: Q4 2025

Mar 2, 2026, 4:30 PM EST - 3 months ago

Quanterix Slides: Q4 2025

2026-03-02T21:06:31.000Z - 3 months ago

Quanterix reports Q4 EPS (49c) vs. (30c) last year

2026-03-02T21:05:34.000Z - 3 months ago

Quanterix sees FY26 revenue $169M-$174M, consensus $168.8M

Mar 2, 2026, 4:01 PM EST - 3 months ago

Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025

Mar 2, 2026, 8:33 AM EST - 3 months ago

Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide

Feb 26, 2026, 8:33 AM EST - 3 months ago

Quanterix to Participate in Upcoming Investor Conferences

Feb 20, 2026, 8:33 AM EST - 3 months ago

Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

2026-02-03T14:25:10.000Z - 4 months ago

Quanterix submits FDA 510(k) for Alzheimer’s disease blood test

Feb 3, 2026, 8:33 AM EST - 4 months ago

Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection

Jan 21, 2026, 8:33 AM EST - 4 months ago

Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling

2026-01-08T21:36:14.000Z - 5 months ago

Quanterix names Everett Cunningham president, CEO

Jan 8, 2026, 4:30 PM EST - 5 months ago

Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

2025-12-22T12:35:19.000Z - 5 months ago

Quanterix publishes Simoa p-Tau 217 assay study in Nature

Dec 22, 2025, 7:30 AM EST - 5 months ago

Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence

2025-12-22T12:06:46.000Z - 5 months ago

Quanterix price target raised to $8 from $5 at Canaccord

2025-11-20T21:21:00.000Z - 6 months ago

Quanterix names Bill Donnelly executive chair

Nov 20, 2025, 4:15 PM EST - 6 months ago

Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

Nov 17, 2025, 5:30 PM EST - 6 months ago

Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring

Nov 10, 2025, 4:30 PM EST - 7 months ago

Quanterix Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 7 months ago

Quanterix Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 7 months ago

Quanterix Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 7 months ago

Quanterix Slides: Q3 2025

2025-11-10T21:05:38.000Z - 7 months ago

Quanterix reports Q3 EPS (73c), consensus (53c)

Nov 10, 2025, 4:01 PM EST - 7 months ago

Quanterix Releases Financial Results for the Third Quarter of 2025

Nov 3, 2025, 7:00 AM EST - 7 months ago

Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025

Sep 24, 2025, 8:00 AM EDT - 8 months ago

Quanterix Proxy statement: Proxy Filing

2025-09-10T13:41:01.000Z - 9 months ago

CMS fee schedule a ‘meaningful positive’ for Quanterix, says Leerink

Aug 25, 2025, 8:00 AM EDT - 9 months ago

Quanterix Proxy statement: Proxy Filing

Aug 21, 2025, 4:30 PM EDT - 10 months ago

Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit

Aug 13, 2025, 3:30 PM EDT - 10 months ago

Quanterix Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 11, 2025, 7:00 AM EDT - 10 months ago

Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference

2025-08-11T08:55:15.000Z - 10 months ago

Quanterix downgraded to Hold from Buy at Canaccord

Aug 8, 2025, 8:00 AM EDT - 10 months ago

Quanterix Proxy statement: Proxy Filing

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Quanterix Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Quanterix Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Quanterix Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Quanterix Slides: Q2 2025

Aug 7, 2025, 4:06 PM EDT - 10 months ago

Quanterix Releases Financial Results for the Second Quarter of 2025

Aug 4, 2025, 4:02 PM EDT - 10 months ago

Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025

2025-08-04T13:35:07.000Z - 10 months ago

Quanterix announces cooperation agreement with Kent Lake Capital

Aug 4, 2025, 9:30 AM EDT - 10 months ago

Quanterix Announces Cooperation Agreement with Kent Lake Capital

2025-07-28T11:25:06.000Z - 10 months ago

Quanterix announces commercial launch of two novel phospho-tau assays

Jul 28, 2025, 7:00 AM EDT - 10 months ago

Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC

Jul 8, 2025, 9:07 AM EDT - 11 months ago

Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

Jun 23, 2025, 7:30 AM EDT - 1 year ago

Quanterix Expands Reach with IVD and Large Reference Labs

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

Jun 9, 2025, 1:20 PM EDT - 1 year ago

Quanterix Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 6, 2025, 9:41 AM EDT - 1 year ago

Quanterix to Present at Goldman Sachs Global Healthcare Conference

May 23, 2025, 2:21 PM EDT - 1 year ago

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

AKYA

May 12, 2025, 4:30 PM EDT - 1 year ago

Quanterix Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Quanterix Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Quanterix Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Quanterix Slides: Q1 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Quanterix Releases Financial Results for the First Quarter of 2025

May 7, 2025, 3:46 PM EDT - 1 year ago

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

AKYA

May 5, 2025, 7:00 AM EDT - 1 year ago

Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

AKYA

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Quanterix and Akoya Biosciences Announce Amended Merger Agreement

AKYA

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Quanterix Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences

AKYA

Apr 7, 2025, 8:15 AM EDT - 1 year ago

Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya

AKYA

Apr 1, 2025, 1:00 AM EDT - 1 year ago

Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Quanterix Proxy statement: Proxy Filing

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences

AKYA

Mar 17, 2025, 4:30 PM EDT - 1 year ago

Quanterix Earnings Call Transcript: Q4 2024

Mar 17, 2025, 4:30 PM EDT - 1 year ago

Quanterix Annual report: Q4 2024

Mar 17, 2025, 4:30 PM EDT - 1 year ago

Quanterix Earnings release: Q4 2024

Mar 17, 2025, 4:30 PM EDT - 1 year ago

Quanterix Slides: Q4 2024

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Quanterix Releases Financial Results for the Fourth Quarter of 2024

Mar 17, 2025, 4:00 PM EDT - 1 year ago

Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call

AKYA

Mar 13, 2025, 1:00 PM EDT - 1 year ago

Quanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix's Proposed Merger with Akoya Biosciences

AKYA

Mar 3, 2025, 8:00 AM EST - 1 year ago

Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

Mar 3, 2025, 6:00 AM EST - 1 year ago

Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition

FinanceLegacy May. 29 at 2:41 PM

$PRZO this one should be next Israel plays are popping one at a time this one has newsss sympathy off $NEXR $PRFX $HUBC $QTRX 🤩🤩

0 · Reply

PLATINUM_TRADES May. 29 at 3:15 AM

$QTRX We in and up nicely with the 50 at $3.29 needs to break for more🩸🩸

0 · Reply

Watchingnow May. 29 at 1:15 AM

$QTRX anyone know the strike on the warrants?

0 · Reply

MBUSA May. 28 at 3:29 PM

$QTRX working

0 · Reply

SuperGreenToday May. 27 at 3:00 AM

0 · Reply

focafoca99 May. 26 at 9:38 PM

$QTRX moves Anthony Catalano into the COO role and gives him a salary, sign-on bonus, and equity package.

0 · Reply

Rufusbird May. 26 at 9:03 PM

3 · Reply

Grateful_84 May. 22 at 3:11 PM

0 · Reply

a2zmicrocap May. 18 at 9:34 PM

$QTRX

1 · Reply

a2zmicrocap May. 18 at 9:33 PM

$QTRX

0 · Reply

SQUEAKSBANDIT May. 18 at 8:45 PM

$QTRX took some today a trade back to 5 is a nearly 100% gain

1 · Reply

Stockelroy May. 12 at 7:25 PM

$QTRX loading up here at $2.99 post 52 week low recently… looking strong and chatter beginning to chatter 💪

0 · Reply

PLATINUM_TRADES May. 12 at 7:15 PM

$QTRX I told u let's break $3.00👇👇👇👇 please... Nobody seen this.... Thank you for the free money

0 · Reply

PLATINUM_TRADES May. 11 at 2:13 PM

$QTRX 62 straight without a loss..... Small profits here but green 🥗 🥗

1 · Reply

PLATINUM_TRADES May. 11 at 8:11 AM

$QTRX Let's break$3.00 please 🌞

0 · Reply

Oxinternet May. 9 at 8:31 PM

$QTRX Someone bought 72,000 shares after hours on Friday.

0 · Reply

vmst1 May. 8 at 1:33 AM

$QTRX Ameriprise Financial has been selling a total of about 4 million shares on days ending on April 30,2026. Ameriprise has only 990,224 shares now. Selling pressure like this sinks the price. Perhaps other institutional/hedge funds also lightened their holdings. The valuation is so depressed now that it should attract buy out offers which may or may not be satisfactory to QTRX BOD. https://www.sec.gov/Archives/edgar/data/1503274/000119312526210789/xslSCHEDULE_13G_X02/primary_doc.xml

1 · Reply

Will2ride1 May. 7 at 3:35 PM

$QTRX luckily sold my position 2 days ago, but man what a hit...may consider jumping back in...watching for now

0 · Reply

SQUEAKSBANDIT May. 7 at 1:46 PM

$QTRX based on the chart someone new this was coming.......whats new???

0 · Reply

SQUEAKSBANDIT May. 7 at 1:42 PM

$QTRX was there any mention of future strategic transactions? or if they would be interested in selling/merging/partnering ? right now market is not buying

0 · Reply

sakuzoh May. 7 at 1:36 PM

$QTRX how low is this gonna go what the hell

0 · Reply

Shane_Drinion May. 7 at 12:57 PM

$QTRX Still not ready for primetime.

1 · Reply

Market Cap	124.83M
Revenue (ttm)	138.90M
Net Income (ttm)	-107.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-77.14%
Debt to Equity Ratio	0.00

Volume	2,909,800
Avg Vol	1,213,188
Day's Range	N/A - N/A
Shares Out	47.11M
Stochastic %K	97%
Beta	1.15
Analysts	Hold
Price Target	$4.33